Latest News Feed
mNEXSPIKE becomes Moderna's third FDA-approved product
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)
Updates 2025 expected revenue range to $1.5 to 2.5 billion
Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billion
Updates 2025 expected ending cash balance to approximately $6.0 billion
Anticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma
As former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise
Milestone marks a significant step toward producing mRNA vaccines in Canada by 2025
New campaign aims to inform and educate the public about the ongoing risks of COVID-19 and the impact the virus continues to have on day-to-day life
Updated vaccines targeting KP.2 variant have been approved by the U.S. FDA and are now available across the country
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval